Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review - Scorecard - MDSpire
Advertisement
Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
Clinical Scorecard: Management of a Patient Exhibiting Atopic Dermatitis, Vitiligo, and Alopecia Areata with Upadacitinib: A Case Study and Review of Existing Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
JAK-STAT signaling pathway dysregulation in AD, vitiligo, and AA.
Target Population
Care Setting
Key Highlights
Rare simultaneous occurrence of severe AD, vitiligo, and AA in a single patient.
Upadacitinib (15 mg daily) led to rapid improvement in symptoms.
Pruritus subsided within days; significant repigmentation observed at one-year follow-up.
Treatment was well-tolerated with sustained effects.
Guideline-Based Recommendations
Diagnosis
Comprehensive clinical evaluation and routine diagnostic procedures including histopathological examinations.
Management
Consider upadacitinib for patients with severe, treatment-refractory AD, vitiligo, and AA.
Monitoring & Follow-up
Regular assessment of SCORAD, VASI, and SALT scores to evaluate treatment efficacy.
Risks
Potential side effects from prior systemic therapies and the need for careful monitoring.
Patient & Prescribing Data
57-year-old male with severe AD, vitiligo, and AA.
Upadacitinib monotherapy resulted in significant clinical improvement.
Clinical Best Practices
Utilize a multi-disease therapy approach targeting shared pathogenic pathways.
Monitor for treatment response using validated scoring systems.
